Profhilo is an innovative hyaluronic acid that corrects/fills natural and induced skin depressions to help ease the physiological process of skin aging, including reducing skin hydration, adjusting dermal elastic fibers and collagen, and improving skin filling defects and dull skin tone.
The Zhitong Finance App learned that recently, Profhilo, a new generation hyaluronic acid complex under FuRui Medical Technology (01696) (that is, sodium hyaluronate solution for injection, Chinese product name: Pufilo TM) was approved by the Hainan Drug Administration and will land in Hainan as a licensed pharmaceutical device.
Profhilo is an innovative hyaluronic acid that corrects/fills natural and induced skin depressions to help ease the physiological process of skin aging, including reducing skin hydration, adjusting dermal elastic fibers and collagen, and improving skin filling defects and dull skin tone.
This product is produced using a unique fermentation technology. It is pure hyaluronic acid without the crosslinking agent BDDE and has good curative efficacy and safety; each 2 ml contains 32 mg of polymer hyaluronic acid and 32 mg of low molecular hyaluronic acid, respectively, with a total content of 64 mg of hyaluronic acid, which is one of the highest concentrations of hyaluronic acid among approved products currently on the market. Unlike other hyaluronic acid products, Profhilo not only has the hydrating and brightening effect of a water light needle, but also has excellent lifting ability. Its macromolecular hyaluronic acid can support the dermis and act as a scaffold. Small-molecule hyaluronic acid stimulates the regeneration of collagen and elastin in the dermal layer, smoothes skin wrinkles and fine lines, and makes the skin young and radiant.
Since its launch, the next-generation hyaluronic acid complex has been popular in many European and American countries, and has won awards such as the Anti-Aging Skin Enhancement Product Award and the European Product Innovation Award.
This approval benefits from resource advantages such as the Lecheng Pioneer District's policy on urgently needed imported pharmaceutical devices, the State Drug Administration's pharmaceutical and medical device regulatory scientific research base, and the country's first real-world data research and evaluation key laboratory. At the same time, it is also a new breakthrough in exploring high-quality development paths in the biohealth industry, which is expected to better meet the people's new demand for innovative international pharmaceutical devices.